Healthcare Industry News: HSMN NewsFeed
News Release - May 3, 2019
New Study From Invitae Highlights the Importance of Multigene Genetic Testing for Uterine Cancer PatientsResults from one of the largest datasets in uterine cancer presented at The American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting
SAN FRANCISCO, May 3, 2019 -- (Healthcare Sales & Marketing Network) -- Researchers from Invitae (NYSE: NVTA), a leading genetics company, will present a study of more than 6,500 patients with uterine cancer showing that genetic testing provided more than 80 percent of patients with information that made them eligible for precision medicine therapies. The study also highlighted the importance of multigene panel testing versus traditional, limited approaches and was presented this week at the 2019 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting.
"Genetic testing for uterine carcinoma has traditionally been limited to a very targeted number of genes that have an association with uterine cancer," said Robert Nussbaum, M.D., chief medical officer of Invitae and one of the authors of the study. "This study revealed that such limited testing misses other cancer genes that are actionable for the prevention, early detection, and treatment of malignancies. Today's multigene panels are affordable and identify these genes at no additional cost, so that patients and their care teams have the complete genetic information they need to develop a personalized path forward. This study also illustrates what we have long championed: the importance of expanding the use of comprehensive genetic testing to all cancer patients who can benefit from it."
According to the study, multigene cancer panel testing identifies clinically actionable pathogenic or likely pathogenic (P/LP) variants that would have otherwise been missed by traditional, targeted genetic testing for uterine cancer. Researchers compared diagnostic yield and clinical actionability in 6,582 patients with uterine cancer using a comprehensive genetic testing panel strategy. The data identified clinically actionable P/LP variants in 15% of the patients. Of these patients, 39% had a P/LP variant in genes other than those typically associated with uterine carcinoma. Among those with a P/LP variant, 32% were eligible for clinical treatment trials, 52% qualified for FDA-approved therapies, and more than 90% had newfound guideline management recommendations.
Invitae offers high-quality and affordable genetic testing for all stages of a woman's life. From planning for a family and a healthy pregnancy to understanding risks for hereditary cancers such as breast, ovarian and uterine cancer, Invitae believes that every woman can benefit from genetic testing.
Invitae Corporation (NYSE: NVTA) is a leading genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. For more information, visit the company's website at invitae.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's research and the importance of multigene testing for cancer patients; and the importance of expanding the use of comprehensive genetic testing for all cancer patients who can benefit from it. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2018. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.
Source: Invitae Corp
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.